Acute Respiratory Syndrome Market Report and Forecast 2023-2031

The global acute respiratory syndrome treatment market size attained a value of USD 860.2 million in 2022, driven by the mutating variants of COVID-19 and other emerging respiratory syndromes. The market is estimated to grow at a CAGR of 10.1% during the forecast period of 2023-2031. With this growth rate, the market value is estimated to reach a value of USD 2045 million by 2031.

Acute Respiratory Syndrome Market: Introduction

The acute respiratory syndrome (ARS) is a severe and potentially fatal respiratory illness caused by a viral infection. The condition can range from mild flu-like symptoms to severe respiratory distress syndrome. The global acute respiratory syndrome treatment market is highly competitive, with key players focusing on research and development activities to develop effective treatment options and strengthen their market position.

Acute Respiratory Syndrome Epidemiology

Acute respiratory syndrome (ARS) is a severe and potentially fatal respiratory illness caused by a viral infection. The incidence of ARS varies by region and age group. According to the World Health Organization, respiratory infections are a leading cause of morbidity and mortality worldwide, with approximately 3.5 million deaths each year attributed to acute lower respiratory infections alone.

The incidence of ARS is highest in developing countries with poor sanitation and healthcare infrastructure. In these countries, respiratory infections are a leading cause of death among children under the age of five. In developed countries, the incidence of ARS is lower, but it remains a significant public health concern, especially among elderly individuals and those with underlying health conditions.

The most common viruses that cause ARS include influenza virus, respiratory syncytial virus (RSV), and coronaviruses, including the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV). The emergence of new viral strains, such as the SARS-CoV-2 virus responsible for the COVID-19 pandemic, highlights the ongoing threat posed by ARS and the need for effective prevention and treatment strategies.

Acute Respiratory Syndrome Market Segmentations

The market can be categorised into drug class, route of administration, treatment channel, and major region.

Market Breakup by Drug Class

• Vasoconstrictor
• Bronchodilators
• Steroids
• Antibiotics
• Nitric Oxide
• Sedatives and Paralytics
• Surfactant
• Others

Market Breakup by Route of Administration

• Oral
• Inhalation
• Parenteral
• Others

Market Breakup by Treatment Channel

• Public
• Private

Acute Respiratory Syndrome Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Acute Respiratory Syndrome Market Scenario

The global acute respiratory syndrome treatment market is expected to witness significant growth during the forecast period of 2023-2031. The market is driven by factors such as the increasing prevalence of respiratory infections, growing demand for effective treatment options, and the availability of advanced healthcare infrastructure in developed countries. North America dominates the market, followed by Europe and the Asia Pacific. The market in North America is driven by the high prevalence of respiratory infections and the availability of advanced healthcare infrastructure. The market in Europe is also expected to grow significantly, with key players focusing on research and development activities to develop effective treatment options. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period, owing to the increasing awareness about respiratory infections and the rising healthcare expenditure in the region.

Key Players in the Global Acute Respiratory Syndrome Market

The report gives an in-depth analysis of the key players involved in the acute respiratory syndrome market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• AIkido Pharma Inc
• Aceto Corporation
• Global BioLife Inc Ltd
• Faron Pharmaceuticals
• PhaseBio Pharmaceuticals
• Sage Therapeutics
• Emergent BioSolutions
• Direct Biologics
• Kiniksa Pharmaceuticals, Ltd
• Biomarck Pharmaceuticals, Ltd
• Athersys, Inc